PRXL2C

Across TCGA pan-cancer cohorts, PRXL2C mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRXL2C data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRXL2C mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRXL2C expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where PRXL2C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.359	0.821	.002	49	view →
LSCC	DFS	Median	All	0.894	0.980	.003	19	view →
PDAC	DFS	Quartile	All	0.813	0.303	.024	6	view →
HNSC	DFS	Median	III,IV	0.908	0.737	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRXL2C–LUAD (OS)

Open the LUAD breakdown →